OptimizeRx Co. (NASDAQ:OPRX) Director James Paul Lang Buys 321,408 Shares

OptimizeRx Co. (NASDAQ:OPRX) Director James Paul Lang purchased 321,408 shares of OptimizeRx stock in a transaction on Friday, March 14th. The shares were acquired at an average price of $7.60 per share, for a total transaction of $2,442,700.80. Following the completion of the transaction, the director now directly owns 389,452 shares of the company’s stock, valued at approximately $2,959,835.20. The trade was a 472.35 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through this hyperlink.

OptimizeRx Stock Performance

NASDAQ:OPRX opened at $8.63 on Friday. The business has a 50 day moving average price of $5.84 and a 200-day moving average price of $5.94. OptimizeRx Co. has a fifty-two week low of $3.78 and a fifty-two week high of $14.13. The firm has a market cap of $158.97 million, a PE ratio of -6.49 and a beta of 1.31. The company has a debt-to-equity ratio of 0.29, a quick ratio of 3.23 and a current ratio of 3.23.

Institutional Trading of OptimizeRx

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. BNP Paribas Financial Markets lifted its stake in OptimizeRx by 189.2% in the third quarter. BNP Paribas Financial Markets now owns 3,690 shares of the company’s stock worth $28,000 after acquiring an additional 2,414 shares during the period. Wells Fargo & Company MN lifted its stake in OptimizeRx by 33.3% in the fourth quarter. Wells Fargo & Company MN now owns 11,208 shares of the company’s stock worth $54,000 after acquiring an additional 2,797 shares during the period. Barclays PLC lifted its stake in OptimizeRx by 13.5% in the fourth quarter. Barclays PLC now owns 30,574 shares of the company’s stock worth $148,000 after acquiring an additional 3,640 shares during the period. Perkins Capital Management Inc. lifted its stake in OptimizeRx by 4.4% in the fourth quarter. Perkins Capital Management Inc. now owns 105,813 shares of the company’s stock worth $514,000 after acquiring an additional 4,450 shares during the period. Finally, Geode Capital Management LLC lifted its stake in OptimizeRx by 1.2% in the fourth quarter. Geode Capital Management LLC now owns 400,621 shares of the company’s stock worth $1,948,000 after acquiring an additional 4,821 shares during the period. Hedge funds and other institutional investors own 76.47% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research analysts have commented on OPRX shares. Lake Street Capital reiterated a “buy” rating and set a $11.00 price target on shares of OptimizeRx in a research report on Tuesday, December 24th. JMP Securities reiterated a “market outperform” rating and set a $8.00 price target on shares of OptimizeRx in a research report on Thursday, February 6th. Stephens started coverage on shares of OptimizeRx in a research report on Friday, December 20th. They set an “equal weight” rating and a $5.50 price target on the stock. B. Riley upgraded shares of OptimizeRx to a “strong-buy” rating in a research report on Wednesday, March 12th. Finally, Royal Bank of Canada reissued a “sector perform” rating and set a $6.00 price objective (down previously from $7.00) on shares of OptimizeRx in a research note on Wednesday, January 8th. Three investment analysts have rated the stock with a hold rating, five have issued a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $9.06.

OptimizeRx Company Profile

OptimizeRx Corporation, a digital health technology company, enables care-focused engagement between life sciences organizations, healthcare providers, and patients at critical junctures throughout the patient care journey. It offers various tech-enabled marketing solutions through its Artificial Intelligence-generated Dynamic Audience and Activation Platform, which enables customers to execute traditional marketing campaigns on its proprietary digital point-of-care network, as well as dynamic marketing campaigns that optimize audiences in real time to increase the value of treatment information for healthcare professionals and patients in response to clinical care events.